Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

Patients with COPD and type 2 diabetes using SGLT2i were much less likely to have ER visits and hospitalizations related to COPD exacerbations.

Cruises are a great way for travelers with COPD to see the world. Most large cruise lines allow passengers to travel with ...

Chronic obstructive pulmonary disease (COPD) presents a significant challenge for both patients and health care providers and discussions of effective management strategies took center stage at CHEST ...

Hope is on the horizon for patients living with chronic obstructive pulmonary disease (COPD). CHEST 2024 in Boston featured a session highlighting emerging bronchoscopic therapies.

Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, ...

Physician orders for life-sustaining treatment (POLST) forms are crucial tools in ensuring that patient treatment preferences ...

The case was dealt with in the Single Justice Procedure, a secretive fast-track courts system which the government is under ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, ...

We recently compiled a list of the 10 Best Hot Stocks To Buy Right Now. In this article, we are going to take a look at where ...